Drugmaker Worried About Impact of FDA Ad Study

Drug Industry Daily
A A
Valeant Pharmaceuticals is objecting to the FDA’s planned eye-tracking study to assess how viewers see risk information in ads because it would exclude individuals wearing bifocals and hard contact lenses.

To View This Article:

Login

Subscribe To Drug Industry Daily